Table 4.
Sensitivity Analyses: Relative risks of Sudden Cardiac Death during Follow-up, according to Log- transformed Continuous values or Pre-specified Threshold levels of NT-proBNP and hsCRP.
| A. Analyses utilizing Alternative Controls matched for Interim Development of CVD | ||||
|---|---|---|---|---|
| Biomarker | RR (95% CI) per 1-SD in Log Variable | P-value | RR (95%CI) for Clinical Cut-Points* | P-value |
| NT-proBNP | ||||
| Model 1 (age, fasting) † | 1.22 (0.94–1.57) | 0.13 | 3.25 (1.33 – 7.92) | 0.01 |
| Multivariate Model‡ | 1.35 (1.00–1.95) | 0.05 | 4.35 (1.49 – 12.6) | 0.01 |
| hsCRP | ||||
| Model 1 (age, fasting) † | 1.30 (1.01–1.68) | 0.04 | 1.36 (0.85–2.17) | 0.21 |
| Multivariate Model‡ | 1.26 (0.92 –1.74) | 0.15 | 1.26 (0.71–2.22) | 043 |
| B. Analyses limited to Women without CVD at baseline (n=68 cases) | ||||
| Biomarker | RR (95% CI) per 1-SD in Log Variable | P-value | RR (95%CI) for Clinical Cut-Points* | P-value |
| NT-proBNP | ||||
| Model 1 (age, fasting) † | 1.32 (0.97 – 1.78) | 0.01 | 6.01 (1.33 – 27.2) | 0.02 |
| Multivariate Model† | 1.54 (1.02 – 2.33) | 0.04 | 4.51 (0.77 – 26.3) | 0.09 |
| hsCRP | ||||
| Model 1 (age, fasting) † | 1.38 (1.07 – 1.78) | 0.03 | 1.73 (0.98 – 3.08) | 0.06 |
| Multivariate Model‡ | 0.96 (0.61 – 1.48) | 0.84 | 0.80 (0.36 – 1.81) | 0.59 |
| C. Analyses limited to Definite SCDs (n=63 cases) | ||||
| Biomarker | RR (95% CI) per 1-SD in Log Variable | P-value | RR (95%CI) for Clinical Cut-Points* | P-value |
| NT-proBNP* | ||||
| Model 1 (age, fasting) † | 1.43 (1.04 –1.97) | 0.03 | 4.68 (1.48–14.8) | 0.009 |
| Multivariate Model‡ | 1.71 (1.12–2.63) | 0.01 | 19.9 (2.67–149) | 0.004 |
| hsCRP | ||||
| Model 1 (age, fasting) † | 1.46 (1.06 –2.01) | 0.02 | 1.72 (0.93 –3.17) | 0.09 |
| Multivariate Model‡ | 1.48 (0.94–2.33) | 0.09 | 2.01 (0.80 –5.04) | 0.14 |
hsCRP (>3.0 mg per liter)32 and NT-pro-BNP (> 389 pg/mL)33.
Model 1: Controlled simultaneously for age and fasting status
Multivariable Model 2: Controlled for variables listed above in Model 1 and history of hypertension, history of diabetes, alcohol consumption (<0.1 g, 0.1–14.9, 15.0 to 29.9, 30+), parental history of myocardial infarction prior to age 60, body-mass index (<25 kg/m2, 25–30 kg/m2, >=30 kg/m2), physical activity (quintiles of metabolic equivalent (MET-hours)), current postmenopausal hormone use, GFR, aspirin use>=22 days/month, triglycerides, TC/HDL-Ratio, and for NTproBNP or hsCRP